… dapagliflozin 10 mg daily or placebo, and showed that dapagliflozin reduced the composite
of cardiovascular … safety of dapagliflozin according to baseline NT-proBNP concentrations in …

… inhibitor dapagliflozin, compared with placebo, led to significant reductions … cardiovascular
death and heart failure hospitalization. We examined the effect of dapagliflozin on NT-proBNP …

… Status in Patients with HF … NT-proBNP after 12 weeks from dapagliflozin compared to
placebo (5), and in the CANDLE trial, NT-proBNP changes were small and comparable to patients …

… NT-proBNP concentrations were associated with greater risk for adverse heart failure or …
When added to standard HF care, both empagliflozin and dapagliflozin reduced rates of …

… In patients with heart failure and reduced ejection fraction, use of dapagliflozin over 12
weeks did not affect mean NT-proBNP but increased the proportion of patients experiencing …

… of dapagliflozin for the management of chronic heart failure. We showed that dapagliflozin
… significantly decrease the frequency of cardiovascular death/hospitalization for heart failure, …

… heart failure with reduced ejection fraction (HFrEF). The cardiovascular (CV) benefits of
dapagliflozin were … Table 2 Efficacy of dapagliflozin in patients with symptomatic heart failure with …

… Three large cardiovascular outcome trials of patients with type 2 diabetes (T2D) found a …
for heart failure (HF) in patients treated with SGLT2i. However, a majority of patients in these …

… Dapagliflozin reduces the risk of de novo heart failure (HF) in diabetics, and it has shown to
improve the prognosis of patients with HF across all ranges of left ventricular … cardiovascular …

… of heart failure (HF) and cardiovascular death in people with type 2 diabetes (T2D) and …
cardiovascular disease. Our aim was to examine the effect of the SGLT2i dapagliflozin on cardiac …